Traitements systémiques de première et de deuxième lignes des patients atteints d’un mélanome cutané métastatique (hors métastase cérébrale) : Recommandations nationales françaises
Didier Cupissol(Institut de Recherche en Cancérologie de Montpellier), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Inna Dygai‐Cochet(Centre Georges François Leclerc), X. Mirabel(American Society of Clinical Oncology), G. Truc(Centre Georges François Leclerc), Laurence Lamant(Centre National de la Recherche Scientifique), B. Sassolas(Centre Hospitalier Régional Universitaire de Brest), V. Mazeau-Woynar(Institut National du Cancer), V. Lubrano(Université Toulouse III - Paul Sabatier), Juliette Thariat(Centre National de la Recherche Scientifique), P. Combemale(Centre Léon Bérard), Anne Mourrégot(Institut de Recherche en Cancérologie de Montpellier), L. Verdoni, P. Modiano(Hôpital Saint-Vincent-de-Paul), François Planchamp, Olivier Tiffet(Centre Hospitalier Universitaire de Saint-Étienne), Stéphane Derrey(Inserm), Sophie Siegrist, M. -E. Rougé Bugat, C. Bédane(Central Michigan University)
Cited by 0
Related Papers
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
|Journal of Clinical Oncology|2012|434
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
|The Lancet Oncology|2015|394
French guidelines on stereoelectroencephalography (SEEG)
|Neurophysiologie Clinique|2017|348